Trials / Terminated
TerminatedNCT00886782
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Advanced and/or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cdc7-inhibitor | Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months |
Timeline
- Start date
- 2009-05-31
- Primary completion
- 2010-08-04
- Completion
- 2010-08-04
- First posted
- 2009-04-23
- Last updated
- 2023-04-28
- Results posted
- 2023-04-28
Locations
6 sites across 3 countries: United States, Canada, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00886782. Inclusion in this directory is not an endorsement.